Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update Q and A

Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update Q and A

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/op/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Naren Ramakrishna

Stock and Other Ownership Interests: Cytecare Cancer Center, Bangalore India

Research Funding: Decimal (Inst)

Carey K. Anders

Honoraria: Eisai, Genentech/Roche, Ipsen, Seattle Genetics, Puma Biotechnology, AstraZeneca, Elucida Oncology, Immunomedics, Athenex

Consulting or Advisory Role: Genentech/Roche, Puma Biotechnology, Eisai, Ipsen, Seattle Genetics, AstraZeneca, Elucida Oncology, Immunomedics

Research Funding: Puma Biotechnology (Inst), Lilly (Inst), Merck (Inst), Nektar (Inst), Tesaro (Inst), Seattle Genetics (Inst), G1 Therapeutics (Inst), Pfizer (Inst), ZION (Inst), Novartis Pharmaceuticals UK Ltd (Inst)

Patents, Royalties, Other Intellectual Property: UpToDate.com, Jones and Bartlett

Travel, Accommodations, Expenses: Eisai

No other potential conflicts of interest were reported.

留言 (0)

沒有登入
gif